This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
30 Mar 2017

Mylan completes acquisition of Cold-EEZE brand

Cold-EEZE is now Mylan's largest US consumer healthcare brand.

Mylan has announced the successful acquisition of the global rights to the Cold-EEZE brand cold remedy line from ProPhase Labs.

The transaction provides Mylan all assets and rights relating to the Cold-EEZE brand, including all US businesses and US and international trademarks. The Cold-EEZE family of brands includes leading over-the-counter (OTC) cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts and oral liquid dose forms in the US.

Mylan CEO Heather Bresch commented: "The completion of this transaction is an important step as we continue to expand our consumer healthcare offerings. Cold-EEZE is now Mylan's largest US consumer healthcare brand and is part of a growing portfolio of over-the-counter products in the US. Mylan is committed to providing access to the medications that patients need, whether they are in front of or behind the pharmacy counter. We look forward to serving this loyal customer base and supporting this well-known brand."

Related News